Global PCSK9 Inhibitors Market

Report ID : 1298 | Published : 2022-07-06 | Pages: | Format: PDF/EXCEL

The Global PCSK9 Inhibitors Market is expected to grow at a 14.7 % CAGR during the projected period.

Low-density lipoprotein (LDL) receptor degradation is controlled by the proprotein convertase subtilisin/Kexin type 9 serine protease (PCSK9), which reduces the clearance of circulating LDL particles.  PCSK9 inhibitors have been developed as a consequence of controlling PSCK9 levels.  LDL clearance from the blood is inhibited by PCSK9's attachment to low-density lipoprotein receptors (LDLRs), which causes blood levels of LDL to increase. The PCSK9 enzyme is now inhibited with the use of a PCSK9 inhibitor, which increases the number of LDL receptors that can remove LDL from circulation.

Due to a number of factors, comprising an increase in global healthcare spending, a rise in statin resistance among patients with familial hypercholesterolemia, an increase in the risk of cardiovascular diseases like myocardial infarction and coronary revascularization, etc., the PCSK9 Inhibitors market dynamics are anticipated to change in the upcoming years.  The market for PCSK9 Inhibitors will grow significantly if PCSK9 inhibition is used as a preventative approach to reduce the burden of CVD.  The market for PCSK9 inhibitors is also expected to expand due to the effects of these drugs in new therapeutic fields.

Despite the fact that monoclonal antibodies have shown to be the most therapeutically effective PCSK9 inhibitors, additional novel medications are now undergoing various phases of research and will soon be on the market for PCSK9 inhibitors.

Market Segmentation:

The PCSK9 Inhibitors Market is segmented based on Product Type and Application. Based on product type, the market is segmented as Epatha(Evolocumab), Praluent(Alirocumab), Bococizumab, and Others. Based on application, the market is segmented as Clinical Application, Drug Development, and Other. Based on product type, the Epatha(Evolocumab) segment is accounted as a major contributor in the PCSK9 Inhibitors Market.

Amgen's Evolocumab is a monoclonal antibody targeted to treat hyperlipidemia. It is an FDA-approved subcutaneous injection for those on maximum statin therapy who still need extra LDL-cholesterol lowering. It is approved as an adjuvant to existing first-line therapy for both homozygous and heterozygous familial cholesterolemia. Evolocumab is a human IgG2 monoclonal antibody that targets the subtilisin/kexin type 9 proprotein convertase (PCSK9). PCSK9 is a protein that degrades LDL receptors, impairing the liver's capacity to eliminate LDL-cholesterol (LDL-C), or "bad" cholesterol, from the blood. Evolocumab is intended to bind to PCSK9 and prevent it from connecting to LDL receptors on the liver surface, resulting in more LDL receptors on the liver surface to remove LDL-C from the circulation. Evolocumab is the second PCSK9 inhibitor to be approved, following alirocumab.

Based on application, the Clinical Application segment is a major contributor to the PCSK9 Inhibitors Market.

The use of PCSK9 Inhibitors in clinics has increased in recent years. Since PCSK9 is an enzyme that regulates low-density lipoprotein (LDL) receptors and LDL cholesterol concentrations, inhibiting this enzyme may thereby lessen the prevalence of ischemic heart disease. This factor is propelling the use of PCSK9 Inhibitors in clinics. With the convenience of receiving treatment, the number of clinics has been rising. The expansion of clinics has cleared the door for more conventional treatments, diagnostics, and immunizations, particularly for travelling people, as they may readily obtain medical treatment without an appointment.

The North America PCSK9 Inhibitors Market holds significant revenue share in the region.

North America is likely to account for a substantial portion of the global PCSK9 inhibitors market during the forecast period because of the presence of well-established enterprises producing and marketing PCSK9 inhibitors. According to the US Department of Health and Human Services, around 805,000 Americans have a heart attack each year. This highlights the importance of medications like PCSK9 inhibitors in lowering cholesterol and preventing heart disease at an early stage. The region's high prevalence of cardiovascular illnesses, combined with new product releases, will drive PCSK9 inhibitor growth in the region. Furthermore, expanding R&D activities and increased awareness and prevalence of risk factors such as diabetes in the general population are expected to drive the North American market during the forecast period.

Competitive Landscape

The key players in the PCSK9 Inhibitors Market have shifted their focus towards bio-based components for product manufacturing and are initiating significant strategies such as mergers, acquisitions, and joint ventures of major and domestic firms to improve their global market reach and product portfolio. Some of the primary key players in the PCSK9 Inhibitors Market are Amgen, Eli Lilly, Sanofi, Pfizer, Novartis, Roche, Merck, Alnylam, AstraZeneca, Affiris, BMS, Ionis Pharmaceuticals, Cyon Therapeutics, and Daiichi Sankyo.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Cell Therapy Packaging Products and Services Market Snapshot

Chapter 4. Global Cell Therapy Packaging Products and Services Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Therapy Estimates & Trend Analysis

5.1. By Therapy & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Therapy:

5.2.1. T-cell Therapies

5.2.2. Dendritic Cell Vaccines

5.2.3. Stem Cell Therapies

5.2.4. NK Cell Therapies

5.2.5. Other ATMPs

Chapter 6. Market Segmentation 2: By Package Engineering Design Estimates & Trend Analysis

6.1. By Package Engineering Design & Market Share, 2020 & 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Package Engineering Design:

6.2.1. Primary Packaging

6.2.2. Secondary Packaging

Chapter 7. Market Segmentation 3: By Scale of Operations Estimates & Trend Analysis

7.1. By Scale of Operation & Market Share, 2020 & 2030

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Scale of Operation:

7.2.1. Clinical

7.2.2. Commercial

Chapter 8. Cell Therapy Packaging Products and Services Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Cell Therapy Packaging Products and Services Market revenue (US$ Million) estimates and forecasts By Therapy, 2020-2030

8.1.2. North America Cell Therapy Packaging Products and Services Market revenue (US$ Million) estimates and forecasts By Package Engineering Design, 2020-2030

8.1.3. North America Cell Therapy Packaging Products and Services Market revenue (US$ Million) estimates and forecasts by Scale of Operation, 2020-2030

8.1.4. North America Cell Therapy Packaging Products and Services Market revenue (US$ Million) estimates and forecasts by country, 2020-2030

8.2. Europe

8.2.1. Europe Cell Therapy Packaging Products and Services Market revenue (US$ Million) By Therapy, 2020-2030

8.2.2. Europe Cell Therapy Packaging Products and Services Market revenue (US$ Million) By Package Engineering Design, 2020-2030

8.2.3. Europe Cell Therapy Packaging Products and Services Market revenue (US$ Million) estimates and forecasts by Scale of Operation, 2020-2030

8.2.4. Europe Cell Therapy Packaging Products and Services Market revenue (US$ Million) by country, 2020-2030

8.3. Asia Pacific

8.3.1. Asia Pacific Cell Therapy Packaging Products and Services Market revenue (US$ Million) By Therapy, 2020-2030

8.3.2. Asia Pacific Cell Therapy Packaging Products and Services Market revenue (US$ Million) By Package Engineering Design, 2020-2030

8.3.3. Asia Pacific Cell Therapy Packaging Products and Services Market revenue (US$ Million) estimates and forecasts by Scale of Operation, 2020-2030

8.3.4. Asia Pacific Cell Therapy Packaging Products and Services Market revenue (US$ Million) by country, 2020-2030

8.4. Latin America

8.4.1. Latin America Cell Therapy Packaging Products and Services Market revenue (US$ Million) By Therapy, (US$ Million)

8.4.2. Latin America Cell Therapy Packaging Products and Services Market revenue (US$ Million) By Package Engineering Design, (US$ Million)

8.4.3. Latin America Cell Therapy Packaging Products and Services Market revenue (US$ Million) estimates and forecasts by Scale of Operation, 2020-2030

8.4.4. Latin America Cell Therapy Packaging Products and Services Market revenue (US$ Million) by country, 2020-2030

8.5. Middle East & Africa

8.5.1. Middle East & Africa Cell Therapy Packaging Products and Services Market revenue (US$ Million) By Therapy, (US$ Million)

8.5.2. Middle East & Africa Cell Therapy Packaging Products and Services Market revenue (US$ Million) By Package Engineering Design, (US$ Million)

8.5.3. Middle East & Africa Cell Therapy Packaging Products and Services Market revenue (US$ Million) estimates and forecasts by Scale of Operation, 2020-2030

8.5.4. Middle East & Africa Cell Therapy Packaging Products and Services Market revenue (US$ Million) by country, 2020-2030

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Almac

9.2.2. Catalent Pharma Solutions

9.2.3. Cryoport Systems

9.2.4. Core Cryolab Inc.

9.2.5. Yourway

9.2.6. Lufthansa Cargo

9.2.7. Saint-Gobain Life Sciences

9.2.8. Thermo Fisher Scientific

9.2.9. West Pharmaceutical Services

9.2.10. Chart Industries Inc.

9.2.11. OPTIMA packaging group GmbH

9.2.12. Creative Biolabs

9.2.13. Körber Medipak Systems GmbH

9.2.14. Lonza

9.2.15. Adept Group LLC

Other Prominent Players

Segmentation of PCSK9 Inhibitors Market-

By Product Type

  • Epatha(Evolocumab)
  • Praluent(Alirocumab)
  • Bococizumab
  • Others

By Application

  • Clinical Application
  • Drug Development
  • Other

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa

Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients